Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1600RXA

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	NOV 21	CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present
NEWS 3	NOV 26	MARPAT enhanced with FSORT command
NEWS 4	NOV 26	CHEMSAFE now available on STN Easy
NEWS 5	NOV 26	Two new SET commands increase convenience of STN searching
NEWS 6	DEC 01	ChemPort single article sales feature unavailable
NEWS 7	DEC 12	GBFULL now offers single source for full-text coverage of complete UK patent families
NEWS 8	DEC 17	Fifty-one pharmaceutical ingredients added to PS
NEWS 9	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS 10	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data
NEWS 11	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS 12	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS 13	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS 14	FEB 10	COMPENDEX reloaded and enhanced
NEWS 15	FEB 11	WTEXTILES reloaded and enhanced
NEWS 16	FEB 19	New patent-examiner citations in 300,000 CA/CAplus patent records provide insights into related prior art
NEWS 17	FEB 19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS 18	FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS 19	FEB 23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS 20	FEB 23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS 21	FEB 23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS 22	FEB 25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS 23	MAR 06	INPADOCDB and INPAFAMDB enhanced with new display formats
NEWS 24	MAR 11	EPFULL backfile enhanced with additional full-text applications and grants
NEWS 25	MAR 11	ESBIOBASE reloaded and enhanced
NEWS 26	MAR 20	CAS databases on STN enhanced with new super role for nanomaterial substances
NEWS 27	MAR 23	CA/CAplus enhanced with more than 250,000 patent equivalents from China

```
 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS     STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN     Welcome Banner and News Items
 NEWS IPC8      For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 07:39:37 ON 24 MAR 2009

=> fil reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.22       0.22

FILE 'REGISTRY' ENTERED AT 07:40:01 ON 24 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   22 MAR 2009  HIGHEST RN 1125392-64-4
DICTIONARY FILE UPDATES:  22 MAR 2009  HIGHEST RN 1125392-64-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\QUERIES\10596129.str
```



chain nodes :
10 12 13 14
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
12-13 13-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 12-13 13-14

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 07:40:39 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     1653 TO ITERATE

100.0% PROCESSED     1653 ITERATIONS                                 2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        30621 TO    35499
PROJECTED ANSWERS:               2 TO      124

L2            2 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 07:40:42 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    33311 TO ITERATE

100.0% PROCESSED    33311 ITERATIONS                               65 ANSWERS
SEARCH TIME: 00.00.01

L3           65 SEA SSS FUL L1

=> s l3 and caplus/lc
      64233141 CAPLUS/LC
L4           48 L3 AND CAPLUS/LC

=> s l3 and l4
L5           48 L3 AND L4

=> s l3 not l4
```

L6 17 L3 NOT L4

=> d l6 1-17

L6 ANSWER 1 OF 17 REGISTRY COPYRIGHT 2009 ACS on STN
RN 889771-82-8 REGISTRY
ED Entered STN: 28 Jun 2006
CN INDEX NAME NOT YET ASSIGNED
MF C23 H15 N3 O2 S
SR Chemical Library
Supplier: Princeton BioMolecular Research, Inc.
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 ANSWER 2 OF 17 REGISTRY COPYRIGHT 2009 ACS on STN
RN 873680-12-7 REGISTRY
ED Entered STN: 07 Feb 2006
CN INDEX NAME NOT YET ASSIGNED
MF C28 H16 Br N3 O4
SR Chemical Library
Supplier: Otava
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 ANSWER 3 OF 17 REGISTRY COPYRIGHT 2009 ACS on STN
RN 695219-63-7 REGISTRY
ED Entered STN: 18 Jun 2004
CN 2-Furancarboxamide, N-(5,6-di-2-furanylfuro[2,3-d]pyrimidin-4-yl)-N-(2-furanylcarbonyl)- (CA INDEX NAME)
MF C24 H13 N3 O7
SR Chemical Library
Supplier: Chemical Block Ltd.
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 ANSWER 4 OF 17 REGISTRY COPYRIGHT 2009 ACS on STN
RN 679418-63-4 REGISTRY
ED Entered STN: 04 May 2004
CN Benzeneacetamide, N-[6-(4-chlorophenyl)-5-phenylfuro[2,3-d]pyrimidin-4-yl]-α-phenyl- (CA INDEX NAME)
MF C32 H22 Cl N3 O2
SR Chemical Library
Supplier: TimTec, Inc.
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 ANSWER 5 OF 17 REGISTRY COPYRIGHT 2009 ACS on STN
RN 508186-43-4 REGISTRY
ED Entered STN: 01 May 2003
CN Benzeneacetamide, N-(6-[1,1'-biphenyl]-4-yl-5-phenylfuro[2,3-d]pyrimidin-4-yl)-α-phenyl- (CA INDEX NAME)
MF C38 H27 N3 O2
SR Chemical Library
Supplier: Interchim
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 ANSWER 6 OF 17 REGISTRY COPYRIGHT 2009 ACS on STN
RN 508186-42-3 REGISTRY
ED Entered STN: 01 May 2003
CN Benzeneacetamide, N-(5,6-di-2-furanylfuro[2,3-d]pyrimidin-4-yl)-α-phenyl- (CA INDEX NAME)
MF C28 H19 N3 O4
SR Chemical Library
Supplier: Interchim
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 ANSWER 7 OF 17 REGISTRY COPYRIGHT 2009 ACS on STN
RN 508186-41-2 REGISTRY
ED Entered STN: 01 May 2003
CN Benzamide, 3-bromo-N-(5,6-di-2-furanylfuro[2,3-d]pyrimidin-4-yl)-4-methoxy- (CA INDEX NAME)
MF C22 H14 Br N3 O5
SR Chemical Library
Supplier: Interchim



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 ANSWER 8 OF 17 REGISTRY COPYRIGHT 2009 ACS on STN
RN 461438-47-1 REGISTRY
ED Entered STN: 15 Oct 2002
CN Benzamide, 2-bromo-N-(5,6-diphenylfuro[2,3-d]pyrimidin-4-yl)- (CA INDEX NAME)
MF C25 H16 Br N3 O2
SR Chemical Library
Supplier: Ambinter
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 ANSWER 9 OF 17 REGISTRY COPYRIGHT 2009 ACS on STN
RN 461431-13-0 REGISTRY
ED Entered STN: 15 Oct 2002
CN Benzamide, 2-chloro-N-(5,6-diphenylfuro[2,3-d]pyrimidin-4-yl)- (CA INDEX NAME)
MF C25 H16 Cl N3 O2
SR Chemical Library
Supplier: Ambinter
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 ANSWER 10 OF 17 REGISTRY COPYRIGHT 2009 ACS on STN
RN 442534-24-9 REGISTRY
ED Entered STN: 05 Aug 2002
CN Acetamide, N-(5,6-diphenylfuro[2,3-d]pyrimidin-4-yl)-2-phenoxy- (CA INDEX NAME)
MF C26 H19 N3 O3
SR Chemical Library
Supplier: Interchim
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 ANSWER 11 OF 17 REGISTRY COPYRIGHT 2009 ACS on STN
RN 441738-70-1 REGISTRY
ED Entered STN: 01 Aug 2002
CN 2-Furancarboxamide, N-(5,6-diphenylfuro[2,3-d]pyrimidin-4-yl)- (CA INDEX NAME)
MF C23 H15 N3 O3
SR Chemical Library
Supplier: TimTec, Inc.
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 ANSWER 12 OF 17 REGISTRY COPYRIGHT 2009 ACS on STN
RN 441738-69-8 REGISTRY
ED Entered STN: 01 Aug 2002
CN Benzamide, N-(5,6-diphenylfuro[2,3-d]pyrimidin-4-yl)-4-methyl- (CA INDEX NAME)
MF C26 H19 N3 O2
SR Chemical Library
Supplier: PHARMEKS Ltd.
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 ANSWER 13 OF 17 REGISTRY COPYRIGHT 2009 ACS on STN
RN 441738-68-7 REGISTRY
ED Entered STN: 01 Aug 2002
CN Propanamide, N-(5,6-diphenylfuro[2,3-d]pyrimidin-4-yl)-2,2-dimethyl- (CA INDEX NAME)
MF C23 H21 N3 O2
SR Chemical Library
Supplier: Ambinter
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 ANSWER 14 OF 17 REGISTRY COPYRIGHT 2009 ACS on STN
RN 434291-48-2 REGISTRY
ED Entered STN: 27 Jun 2002
CN Benzamide, N-(5,6-diphenylfuro[2,3-d]pyrimidin-4-yl)-4-fluoro- (CA INDEX NAME)
MF C25 H16 F N3 O2
SR Chemical Library
Supplier: Interchim
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 ANSWER 15 OF 17 REGISTRY COPYRIGHT 2009 ACS on STN
RN 426216-41-3 REGISTRY
ED Entered STN: 06 Jun 2002
CN Benzamide, N-[6-(4-chlorophenyl)-5-phenylfuro[2,3-d]pyrimidin-4-yl]-4-nitro- (CA INDEX NAME)
MF C25 H15 Cl N4 O4
SR Chemical Library
Supplier: ChemBridge Corporation
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 ANSWER 16 OF 17 REGISTRY COPYRIGHT 2009 ACS on STN
RN 339060-72-9 REGISTRY
ED Entered STN: 31 May 2001
CN Benzamide, N-(5,6-diphenylfuro[2,3-d]pyrimidin-4-yl)-3-nitro- (CA INDEX NAME)
MF C25 H16 N4 O4
SR Chemical Library
Supplier: Ambinter
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 ANSWER 17 OF 17 REGISTRY COPYRIGHT 2009 ACS on STN
RN 324066-73-1 REGISTRY
ED Entered STN: 26 Feb 2001
CN Acetamide, N-(5,6-diphenylfuro[2,3-d]pyrimidin-4-yl)- (CA INDEX NAME)
MF C20 H15 N3 O2
SR Chemical Library
      Supplier: Oak Samples Ltd.
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

```
=> fil caplus
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                       227.04     227.26

FILE 'CAPLUS' ENTERED AT 07:41:56 ON 24 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 24 Mar 2009  VOL 150 ISS 13
FILE LAST UPDATED: 23 Mar 2009  (20090323/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d his

     (FILE 'HOME' ENTERED AT 07:39:37 ON 24 MAR 2009)

     FILE 'REGISTRY' ENTERED AT 07:40:01 ON 24 MAR 2009
L1             STRUCTURE UPLOADED
L2               2 S L1
L3              65 S L1 FULL
L4              48 S L3 AND CAPLUS/LC
L5              48 S L3 AND L4
L6              17 S L3 NOT L4

     FILE 'CAPLUS' ENTERED AT 07:41:56 ON 24 MAR 2009

=> s l4
L7          13 L4

=> d ibib abs hitstr 1-13
```

L7 ANSWER 1 OF 13 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:674351 CAPLUS
DOCUMENT NUMBER: 149:7030
TITLE: Single nucleotide polymorphisms in the human genome associated with an increased susceptibility to type 2 diabetes
INVENTOR(S): Steinthorsdottir, Valgerdur; Thorleifsson, Gudmar
PATENT ASSIGNEE(S): Decode Genetics Ehf., Iceland
SOURCE: PCT Int. Appl., 184pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008065682	A2	20080605	WO 2007-IS20	20071130
WO 2008065682	A3	20081016		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.:		
IS 2006-8572	A	20061130
IS 2007-8630	A	20070404

AB Association anal. has shown that certain genetic variants are susceptibility
variants for Type 2 diabetes. The invention relates to diagnostic applications of such susceptibility variants, including methods of determining
increased susceptibility to Type 2 diabetes, as well as methods of determining
decreased susceptibility to Type 2 diabetes in an individual. The invention further relates to kits for determining a susceptibility to Type 2
diabetes based on the variants described herein.

IT 744255-23-0, GW 784752x
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(SNPs affecting response to; SNPs in human genome associated with increased susceptibility to type 2 diabetes)

RN 744255-23-0 CAPLUS
CN Cyclopentanecarboxamide, N-[6-(3-pyridinyl)furo[2,3-d]pyrimidin-4-yl]- (CA INDEX NAME)

L7 ANSWER 1 OF 13 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L7 ANSWER 2 OF 13 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:630237 CAPLUS
DOCUMENT NUMBER: 147:252819
TITLE: Identification and Biochemical Studies on Novel Non-Nucleoside Inhibitors of the Enzyme Adenosine Kinase
AUTHOR(S): Park, Jae; Vaidyanathan, Gayathri; Singh, Bhag; Gupta, Radhey S.
CORPORATE SOURCE: Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, L8N 3Z5, Can.
SOURCE: Protein Journal (2007), 26(3), 203-212
CODEN: PJROAH; ISSN: 1572-3887
PUBLISHER: Springer
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The enzyme adenosine kinase (AK) plays a key role in the regulation of intracellular and extracellular concentration of adenosine (Ado), which exhibits
potent hormonal activity in cardiovascular, nervous and immune systems. In view of the pharmacol. effects of Ado, there is much interest in identifying inhibitors of AK, which can augment its tissue-protective effects. In this study, we have screened 1040 compds. from a chemical library of putative kinase inhibitors for their effect on purified human recombinant AK. These studies have identified 8 novel, non-nucleoside AK inhibitors. Four of these compds. (viz. 2-tert-butyl-4H-benzo[1,2,4]thiadiazine-3-thione (2759-0749); N-(5,6-diphenyl-furo[2,3-d]pyrimidin-4-yl)-propionamide (3998-0118); 3-[5,6-Bis-(4-methoxy-phenyl)-furo[2,3-d]pyrimidin-4-ylamino]-propan-1-ol (4072-2732); and 2-[2-(3,4-dihydroxy-phenyl)-5-phenyl-1H-imidazol-4-yl]-fluoren-9-one (8008-6198)), which inhibited human AK in a concentration-dependent
manner in a low micromolar range (IC50 = 0.38.apprx.1.98 μM) were further studied. Kinetic and structural studies on these compds. provide evidence that inhibition of AK by these compds. was competitive with respect to Ado and non-competitive for ATP. All of these compds. also inhibited uptake of Ado and its metabolism in cultured mammalian cells at comparable concns. indicating their efficient cellular penetrability. These AK inhibitors, whose chemical structures differ significantly from all
previously known inhibitors, provide useful lead compds. for identification of more potent but less toxic AK inhibitors that may prove useful for therapeutic purposes.

IT 441738-67-6
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(non-nucleoside inhibitors of adenosine kinase)

RN 441738-67-6 CAPLUS
CN Propanamide, N-(5,6-diphenylfuro[2,3-d]pyrimidin-4-yl)- (CA INDEX NAME)



L7 ANSWER 2 OF 13 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 13 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:566890 CAPLUS
DOCUMENT NUMBER: 147:180515
TITLE: Virtual Screening Studies to Design Potent CDK2-Cyclin A Inhibitors
AUTHOR(S): Vadivelan, S.; Sinha, Barij Nayan; Irudayam, Sheeba Jem; Jagarlapudi, Sarma A. R. P.
CORPORATE SOURCE: GVK Biosciences Pvt. Ltd., Hyderabad, 500037, India
SOURCE: Journal of Chemical Information and Modeling (2007), 47(4), 1526-1535
CODEN: JCISD8; ISSN: 1549-9596
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The cell division cycle is controlled by cyclin-dependent kinases (CDK), which consist of a catalytic subunit (CDK1-CDK8) and a regulatory subunit (cyclin A-H). Pharmacophore anal. indicates that the best inhibitor model consists of (1) two hydrogen bond acceptors, (2) one hydrogen bond donor, and (3) one hydrophobic feature. The HypoRefine pharmacophore model gave an enrichment factor of 1.31 and goodness of fit score of 0.76. Docking studies were carried out to explore the structural requirements for the CDK2-cyclin A inhibitors and to construct highly predictive models for the design of new inhibitors. Docking studies demonstrate the important role of hydrogen bond and hydrophobic interactions in determining the inhibitor-receptor binding affinity. The validated pharmacophore model is further used for retrieving the most active hits/lead from a virtual library of mols. Subsequently, docking studies were performed on the hits, and novel series of potent leads were suggested based on the interaction energy between CDK2-cyclin A and the putative inhibitors.

IT 744255-18-3 744255-23-0
RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)
(virtual screening studies to design CDK2-cyclin A inhibitors)

RN 744255-18-3 CAPLUS
CN Cyclopropanecarboxamide, N-[6-(3-pyridinyl)furo[2,3-d]pyrimidin-4-yl]- (CA INDEX NAME)



RN 744255-23-0 CAPLUS
CN Cyclopentanecarboxamide, N-[6-(3-pyridinyl)furo[2,3-d]pyrimidin-4-yl]- (CA INDEX NAME)

L7 ANSWER 3 OF 13 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



REFERENCE COUNT: 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 13 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:31282 CAPLUS
DOCUMENT NUMBER: 144:128992
TITLE: Preparation of furanopyrimidines for treatment of protein tyrosine kinase-associated diseases
INVENTOR(S): Buchanan, John L.; Buckner, William H.; Burkitt, Simon A.; Dimauro, Erin F.; Farthing, Christopher N.; Frenkel, Alexander David; Harrison, Martin J.; Kayser, Frank; Liu, Jinqian; Lively, Sarah E.; Marshall, Teresa L.; Mcgowan, David C.; Sharma, Rajiv; Shuttleworth, Stephen Joseph; Zhu, Xiaotian
PATENT ASSIGNEE(S): Amgen Inc., USA
SOURCE: PCT Int. Appl., 154 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006004658	A2	20060112	WO 2005-US22727	20050629
WO 2006004658	A3	20060420		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005260077	A1	20060112	AU 2005-260077	20050629
CA 2571857	A1	20060112	CA 2005-2571857	20050629
US 20060040961	A1	20060223	US 2005-169312	20050629
EP 1768986	A2	20070404	EP 2005-763716	20050629
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2008505084	T	20080221	JP 2007-519333	20050629
MX 2006015223	A	20071109	MX 2006-15223	20061220
PRIORITY APPLN. INFO.:			US 2004-583898P P	20040629
			US 2005-659947P P	20050308
			WO 2005-US22727 W	20050629

OTHER SOURCE(S): CASREACT 144:128992; MARPAT 144:128992
GI

L7 ANSWER 4 OF 13 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



I



II

AB The title compds. I [X = NR2R3, OR2, SR2; Y = H, halo, haloalkyl, etc.; Z = O, SOp (p = 0-2); R1 = (un)substituted alkenyl, alkynyl, aryl, etc.; R1a = H, F, Cl, Br, I, CF3, alkyl, haloalkyl, alkoxy; R2 = (un)substituted alkyl, cycloalkyl, aralkyl, etc.; R3 = H, CF3, alkyl], useful for treating and/or preventing protein tyrosine kinase-associated disorders, were prepared E.g., a multi-step synthesis of II, starting from 5-phenylfuro[2,3-d]pyrimidin-4(3H)-one, was given. The exemplified compds. I were tested and found to exhibit IC50 values of at least <10 μM in any one of the described assays (e.g., LCK kinase assay, ACK1 enzymic assay, etc.). The invention also includes pharmaceutical compns. comprising a compound I, methods of treating various diseases and conditions in a mammal, including inflammation, inhibition of T cell activation, proliferation, arthritis, organ transplant, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease, Crohn's disease, lupus, hypersensitivity, type 1 diabetes, psoriasis, dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Addison's disease, autoimmune diseases, glomerulonephritis, allergic diseases, asthma, hayfever, eczema, cancer, colon carcinoma and thymoma, comprising administering to the mammal a therapeutically effective amount of a compound I. The invention also relates to methods of manufacturing medicaments, which comprise one or more compds. I.

IT 873306-45-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of furanopyrimidines for treatment of protein tyrosine kinase-associated diseases)

RN 873306-45-7 CAPLUS
CN Imidodicarbonic acid, N-(5-bromo-6-phenylfuro[2,3-d]pyrimidin-4-yl)-, C,C'-bis(1,1-dimethylethyl) ester (CA INDEX NAME)

L7 ANSWER 4 OF 13 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L7 ANSWER 5 OF 13 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:1075801 CAPLUS
DOCUMENT NUMBER: 143:367316
TITLE: Preparation of furo[2,3-d]pyrimidines as inhibitors of DDR2 (discoidin domain receptor 2) tyrosine kinase.
INVENTOR(S): Yang, Beom-Seok; Yang, Kyung-Mi; Kim, Hae-Jong; Park, In-Sung; Park, Sung-Dae; Lee, Jang-Hyuk; Kwon, Hyuk-Man; Woo, Byoung-Young
PATENT ASSIGNEE(S): Korea Institute of Science and Technology, S. Korea; Jeil Pharmaceutical Co., Ltd.
SOURCE: PCT Int. Appl., 106 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005092896	A1	20051006	WO 2005-KR19	20050105
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
KR 2005091462	A	20050915	KR 2004-16922	20040312
KR 2007012648	A	20070126	KR 2006-718588	20060911
KR 883909	B1	20090217		
PRIORITY APPLN. INFO.:			KR 2004-16922 A	20040312
			WO 2005-KR19 W	20050105

OTHER SOURCE(S): CASREACT 143:367316; MARPAT 143:367316
GI



I

AB Title compds. [I; Z = O, S, NH; n = 0-4; R = H, halo, cyano, NO2, OH, amino, CO2H, CONH2, CSNH2, amidine, alkyl, haloalkyl, alkoxy, alkylamino, alkylthio, alkylamide, acylamino, acyloxy, etc.; R1 = H, halo, cyano, NO2,

L7 ANSWER 5 OF 13 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

OH, amino, CO2H, CONH2, CSNH2, amidine, alkyl, haloalkyl, alkoxy, halobenzyloxy, etc.; R2 = H, halo, cyano, NO2, OH, amino, CO2H, CONH2, CSNH2, alkyl, haloalkyl, Ph, halophenyl, etc.; R3 = H, alkyl, haloalkyl, alkoxy, alkylamino, alkylthio, alkylamide, acyloxy, acylamino, haloalkyl, alkoxy, halophenyl, etc.; A = benzene, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, triazole, pyrazole, pyrazine, pyridazine, pyrimidine, cyclohexyl, piperidine, morpholine ring], were prepd. Thus, 3-methoxyphenol was stirred 10 min. with NaH in THF; 4-chloro-5-methyl-6-(4-chlorophenyl)furo[2,3-d]pyrimidine (prepn. given) was added followed by stirring for 2 h at room temp. to give 49% 4-(3-methoxyphenoxy)-5-methyl-6-(4-chlorophenyl)furo[2,3-d]pyrimidine. The latter inhibited DDR2 tyrosine kinase with IC50 <100 μM.

IT 866182-58-3P 866182-59-4P 866182-60-7P
866182-61-8P 866182-62-9P 866182-63-0P
866182-64-1P 866182-65-2P 866182-66-3P
866182-74-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of furopyrimidines as inhibitors of DDR2 tyrosine kinase)

RN 866182-58-3 CAPLUS
CN Acetamide, N-[6-(4-chlorophenyl)furo[2,3-d]pyrimidin-4-yl]- (CA INDEX NAME)



RN 866182-59-4 CAPLUS
CN Benzamide, N-[6-(4-chlorophenyl)furo[2,3-d]pyrimidin-4-yl]-4-methoxy- (CA INDEX NAME)



RN 866182-60-7 CAPLUS

L7 ANSWER 5 OF 13 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

CN Benzamide, N-[6-(4-chlorophenyl)-5-methylfuro[2,3-d]pyrimidin-4-yl]-4-methoxy-N-(4-methoxybenzoyl)- (CA INDEX NAME)



RN 866182-61-8 CAPLUS
CN 1,3-Benzodioxole-5-carboxamide, N-[6-(4-chlorophenyl)-5-methylfuro[2,3-d]pyrimidin-4-yl]- (CA INDEX NAME)



RN 866182-62-9 CAPLUS
CN Benzamide, N-[6-(4-chlorophenyl)furo[2,3-d]pyrimidin-4-yl]-3-methoxy- (CA INDEX NAME)



L7 ANSWER 5 OF 13 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RN 866182-63-0 CAPLUS
CN Benzamide, N-[6-(4-chlorophenyl)-5-ethylfuro[2,3-d]pyrimidin-4-yl]-4-methoxy- (CA INDEX NAME)



RN 866182-64-1 CAPLUS
CN Benzamide, N-[6-(4-chlorophenyl)-5-ethylfuro[2,3-d]pyrimidin-4-yl]-4-hydroxy- (CA INDEX NAME)



RN 866182-65-2 CAPLUS
CN Benzamide, N-[6-(4-fluorophenyl)-5-methylfuro[2,3-d]pyrimidin-4-yl]-4-methoxy- (CA INDEX NAME)

L7 ANSWER 5 OF 13 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 866182-66-3 CAPLUS
CN Acetamide, N-[6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-4-yl]- (CA INDEX NAME)



RN 866182-74-3 CAPLUS
CN Benzamide, N-[6-(4-chlorophenyl)-5-methylfuro[2,3-d]pyrimidin-4-yl]-3-hydroxy- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 13 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:588992 CAPLUS
DOCUMENT NUMBER: 143:115566
TITLE: Preparation of N-(furo[2,3-d]pyrimidin-4-yl) amides as GSK-3 inhibitors
INVENTOR(S): Nakano, Masato; Maeda, Yutaka
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005061516	A1	20050707	WO 2004-US38307	20041117
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1689753	A1	20060816	EP 2004-811132	20041117
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS				
JP 2007513155	T	20070524	JP 2006-542602	20041117
US 20070088031	A1	20070419	US 2006-596129	20060601
PRIORITY APPLN. INFO.:			US 2003-526811P	P 20031204
			WO 2004-US38307	W 20041117

OTHER SOURCE(S): CASREACT 143:115566; MARPAT 143:115566
GI



I



II

AB The title compds. I [U = CH, N; R1 = alkyl, cycloalkyl, CH2CH2SMe; CH2(cycloalkyl), Ph optionally substituted by halo or nitro, morpholino, pyrrolidino; when U = CH, R2 = H, halo, alkyl, OMe ; and when U = N, R2 = H] which are inhibitors of the kinases, such as GSK-3, were prepared E.g, a

L7 ANSWER 6 OF 13 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
multi-step synthesis of II, starting from malononitrile and α-bromo-p-methoxyacetophenone, was given. The compd. II showed pIC50 of 7.0-8.0 against GSK-3.
IT 744255-03-6P 744255-04-7P 744255-05-8P
744255-06-9P 744255-07-0P 744255-08-1P
744255-09-2P 744255-10-5P 744255-11-6P
744255-12-7P 744255-13-8P 744255-14-9P
744255-15-0P 744255-16-1P 744255-17-2P
744255-18-3P 744255-19-4P 744255-20-7P
744255-21-8P 744255-22-9P 744255-23-0P
857663-86-6P 857663-87-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-(furo[2,3-d]pyrimidin-4-yl) amides as GSK-3 inhibitors)
RN 744255-03-6 CAPLUS
CN Hexanamide, N-[6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-4-yl]- (CA INDEX NAME)



RN 744255-04-7 CAPLUS
CN Propanamide, N-[6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-4-yl]-3-(methylthio)- (CA INDEX NAME)



RN 744255-05-8 CAPLUS
CN Propanamide, N-[6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-4-yl]-2-methyl- (CA INDEX NAME)



RN 744255-06-9 CAPLUS
CN Cyclopropanecarboxamide,
N-[6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-4-yl]-
(CA INDEX NAME)



RN 744255-07-0 CAPLUS
CN Cyclopentanecarboxamide,
N-[6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-4-yl]-
(CA INDEX NAME)



RN 744255-08-1 CAPLUS
CN Cyclopentaneacetamide, N-[6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-4-yl]-
(CA INDEX NAME)



RN 744255-09-2 CAPLUS
CN Cyclohexanecarboxamide,
N-[6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-4-yl]-
(CA INDEX NAME)



RN 744255-10-5 CAPLUS
CN 4-Morpholinecarboxamide,
N-[6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-4-yl]-
(CA INDEX NAME)



RN 744255-11-6 CAPLUS
CN 1-Pyrrolidinecarboxamide,
N-[6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-4-yl]-
(CA INDEX NAME)



RN 744255-12-7 CAPLUS
CN Benzamide, 3-fluoro-N-[6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-4-yl]-
(CA
INDEX NAME)



RN 744255-13-8 CAPLUS
CN 2-Furancarboxamide, N-[6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-4-yl]-
(CA
INDEX NAME)



RN 744255-14-9 CAPLUS
CN Cyclopropanecarboxamide, N-(6-phenylfuro[2,3-d]pyrimidin-4-yl)- (CA
INDEX
NAME)



RN 744255-15-0 CAPLUS
CN Cyclopropanecarboxamide,
N-[6-(4-chlorophenyl)furo[2,3-d]pyrimidin-4-yl]-
(CA INDEX NAME)



RN 744255-16-1 CAPLUS
CN Cyclopropanecarboxamide,
N-[6-(4-methylphenyl)furo[2,3-d]pyrimidin-4-yl]-
(CA INDEX NAME)



RN 744255-17-2 CAPLUS
CN Cyclopropanecarboxamide,
N-[6-(4-fluorophenyl)furo[2,3-d]pyrimidin-4-yl]-
(CA INDEX NAME)



RN 744255-18-3 CAPLUS
CN Cyclopropanecarboxamide, N-[6-(3-pyridinyl)furo[2,3-d]pyrimidin-4-yl]-
(CA INDEX NAME)



RN 744255-19-4 CAPLUS
CN Cyclopentanecarboxamide, N-(6-phenylfuro[2,3-d]pyrimidin-4-yl)- (CA INDEX
NAME)



RN 744255-23-0 CAPLUS
CN Cyclopentanecarboxamide, N-[6-(3-pyridinyl)furo[2,3-d]pyrimidin-4-yl]-
(CA INDEX NAME)



RN 857663-86-6 CAPLUS
CN Benzamide, N-[6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-4-yl]-3-nitro- (CA
INDEX NAME)



RN 857663-87-7 CAPLUS
CN Benzamide, N-[6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-4-yl]-4-nitro- (CA
INDEX NAME)



RN 744255-20-7 CAPLUS
CN Cyclopentanecarboxamide,
N-[6-(4-chlorophenyl)furo[2,3-d]pyrimidin-4-yl]-
(CA INDEX NAME)



RN 744255-21-8 CAPLUS
CN Cyclopentanecarboxamide,
N-[6-(4-methylphenyl)furo[2,3-d]pyrimidin-4-yl]-
(CA INDEX NAME)



RN 744255-22-9 CAPLUS
CN Cyclopentanecarboxamide,
N-[6-(4-fluorophenyl)furo[2,3-d]pyrimidin-4-yl]-
(CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:523280 CAPLUS
DOCUMENT NUMBER: 141:199465
TITLE: 4-Acylamino-6-arylfuro[2,3-d]pyrimidines: potent and selective glycogen synthase kinase-3 inhibitors
AUTHOR(S): Maeda, Yutaka; Nakano, Masato; Sato, Hideyuki; Miyazaki, Yasushi; Schweiker, Stephanie L.; Smith, Jeffery L.; Truesdale, Anne T.
CORPORATE SOURCE: Chemistry Department, GlaxoSmithKline K.K., Tsukuba Research Laboratories, Tsukuba, Ibaraki, 300-4247, Japan
SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(15), 3907-3911
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 141:199465
GI



I

AB Modeling studies of a furo[2,3-d]pyrimidine GSK-3 hit compound superimposed onto the X-ray crystal structure of a legacy pyrazolo[3,4-c]pyridazine GSK-3 inhibitor led to the identification of a 4-acylamino-6-arylfuro[2,3-d]pyrimidine template. Synthesis of analogs based on the template has resulted in a number of potent and selective GSK-3β inhibitors. The most potent and selective compound was the m-pyridyl analog I.

IT 744255-03-6P 744255-04-7P 744255-05-8P
744255-06-9P 744255-07-0P 744255-08-1P
744255-09-2P 744255-10-5P 744255-11-6P
744255-12-7P 744255-13-8P 744255-14-9P
744255-15-0P 744255-16-1P 744255-17-2P
744255-18-3P 744255-19-4P 744255-20-7P
744255-21-8P 744255-22-9P 744255-23-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(acylamino arylfuropyrimidines as glycogen synthase kinase-3 inhibitors)

RN 744255-03-6 CAPLUS
CN Hexanamide, N-[6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-4-yl]- (CA INDEX NAME)

L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 744255-07-0 CAPLUS
CN Cyclopentanecarboxamide, N-[6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-4-yl]- (CA INDEX NAME)



RN 744255-08-1 CAPLUS
CN Cyclopentaneacetamide, N-[6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-4-yl]- (CA INDEX NAME)



RN 744255-09-2 CAPLUS
CN Cyclohexanecarboxamide, N-[6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-4-yl]- (CA INDEX NAME)

L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 744255-04-7 CAPLUS
CN Propanamide, N-[6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-4-yl]-3-(methylthio)- (CA INDEX NAME)



RN 744255-05-8 CAPLUS
CN Propanamide, N-[6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-4-yl]-2-methyl- (CA INDEX NAME)



RN 744255-06-9 CAPLUS
CN Cyclopropanecarboxamide, N-[6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-4-yl]- (CA INDEX NAME)

L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 744255-10-5 CAPLUS
CN 4-Morpholinecarboxamide, N-[6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-4-yl]- (CA INDEX NAME)



RN 744255-11-6 CAPLUS
CN 1-Pyrrolidinecarboxamide, N-[6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-4-yl]- (CA INDEX NAME)



RN 744255-12-7 CAPLUS

CN Benzamide, 3-fluoro-N-[6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-4-yl]-(CA
INDEX NAME)



RN 744255-13-8 CAPLUS
CN 2-Furancarboxamide, N-[6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-4-yl]-(CA
INDEX NAME)



RN 744255-14-9 CAPLUS
CN Cyclopropanecarboxamide, N-(6-phenylfuro[2,3-d]pyrimidin-4-yl)- (CA INDEX
NAME)



(CA INDEX NAME)



RN 744255-19-4 CAPLUS
CN Cyclopentanecarboxamide, N-(6-phenylfuro[2,3-d]pyrimidin-4-yl)- (CA INDEX
NAME)



RN 744255-20-7 CAPLUS
CN Cyclopentanecarboxamide,
N-[6-(4-chlorophenyl)furo[2,3-d]pyrimidin-4-yl]-
(CA INDEX NAME)



RN 744255-21-8 CAPLUS
CN Cyclopentanecarboxamide,
N-[6-(4-methylphenyl)furo[2,3-d]pyrimidin-4-yl]-

RN 744255-15-0 CAPLUS
CN Cyclopropanecarboxamide,
N-[6-(4-chlorophenyl)furo[2,3-d]pyrimidin-4-yl]-
(CA INDEX NAME)



RN 744255-16-1 CAPLUS
CN Cyclopropanecarboxamide,
N-[6-(4-methylphenyl)furo[2,3-d]pyrimidin-4-yl]-
(CA INDEX NAME)



RN 744255-17-2 CAPLUS
CN Cyclopropanecarboxamide,
N-[6-(4-fluorophenyl)furo[2,3-d]pyrimidin-4-yl]-
(CA INDEX NAME)



RN 744255-18-3 CAPLUS
CN Cyclopropanecarboxamide, N-[6-(3-pyridinyl)furo[2,3-d]pyrimidin-4-yl]-

(CA INDEX NAME)



RN 744255-22-9 CAPLUS
CN Cyclopentanecarboxamide,
N-[6-(4-fluorophenyl)furo[2,3-d]pyrimidin-4-yl]-
(CA INDEX NAME)



RN 744255-23-0 CAPLUS
CN Cyclopentanecarboxamide, N-[6-(3-pyridinyl)furo[2,3-d]pyrimidin-4-yl]-
(CA INDEX NAME)



L7 ANSWER 8 OF 13 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:950055 CAPLUS
DOCUMENT NUMBER: 140:5065
TITLE: Preparation of pyrazolopyrimidine and furopyrimidine protein kinase inhibitors and their therapeutic use
INVENTOR(S): Hirst, Gavin C.; Arnold, Lee D.; Burchat, Andrew; Wishart, Neil; Calderwood, David; Wada, Carol K.; Michaelides, Michael R.; Ji, Zhiqin; Muckey, Melanie
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 44 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030225098	A1	20031204	US 2003-394965	20030321
PRIORITY APPLN. INFO.:			US 2002-366422P P	20020321

OTHER SOURCE(S): MARPAT 140:5065
GI



I II

AB Title compds. I [X = CR1, NR; Y = O, alkyl, N; Q = N, NR2, O; R3 = H, OH, alkyl, alkoxy; R = H, alkyl, arylalkyl, aryl; R1 = pyrimidinyl, etc.; R2 = piperidinyl, etc.] are prepared For instance, 5-(4-aminophenyl)furo[2,3-d]pyrimidin-4-amine (preparation given) is treated with 1,1-thiocarbonyldiimidazole/pyridine at 0° followed by 2-aminophenol/EDCI and heated to 55° for 8 h to give II. I are useful as kinase inhibitors and are useful in the treatment of hyperproliferative disorders, ulcers, etc.

IT 606099-92-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(pyrazolopyrimidine and furopyrimidine protein kinase inhibitors and their therapeutic use)

RN 606099-92-7 CAPLUS
CN Carbamic acid, [5-[4-[[[(3-bromophenyl)amino]carbonyl]amino]phenyl]-6-methylfuro[2,3-d]pyrimidin-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 8 OF 13 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L7 ANSWER 8 OF 13 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



IT 606099-89-2P 606099-90-5P 606099-91-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(pyrazolopyrimidine and furopyrimidine protein kinase inhibitors and their therapeutic use)

RN 606099-89-2 CAPLUS
CN Carbamic acid, [5-(4-nitrophenyl)furo[2,3-d]pyrimidin-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 606099-90-5 CAPLUS
CN Carbamic acid, [6-bromo-5-(4-nitrophenyl)furo[2,3-d]pyrimidin-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 606099-91-6 CAPLUS
CN Carbamic acid, [6-bromo-5-[4-[[[(3-methylphenyl)amino]carbonyl]amino]phenyl]furo[2,3-d]pyrimidin-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 9 OF 13 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:777596 CAPLUS
DOCUMENT NUMBER: 139:272922
TITLE: Pyrazolopyrimidine and furopyrimidine protein kinase inhibitors and their therapeutic use
INVENTOR(S): Hirst, Gavin C.; Arnold, Lee D.; Burchat, Andrew; Wishart, Neil; Calderwood, David; Wada, Carol K.; Michaelides, Michael R.; Ji, Zhiqin; Muckey, Melanie
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: PCT Int. Appl., 94 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003080064	A1	20031002	WO 2003-US8950	20030321
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20030199525	A1	20031023	US 2002-103098	20020321
CA 2477651	A1	20031002	CA 2003-2477651	20030321
AU 2003222055	A1	20031008	AU 2003-222055	20030321
EP 1496910	A1	20050119	EP 2003-718039	20030321
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005530713	T	20051013	JP 2003-577890	20030321
MX 2004009140	A	20041126	MX 2004-9140	20040921
PRIORITY APPLN. INFO.:			US 2002-103098 A	20020321
			WO 2003-US8950 W	20030321

OTHER SOURCE(S): MARPAT 139:272922

AB The present application is directed to pyrazolopyrimidine and furopyrimidine analogs which are useful as protein kinase inhibitors. These compds. may be used in treatment of hyperproliferative disorders, ulcers, etc.

IT 606099-92-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(pyrazolopyrimidine and furopyrimidine protein kinase inhibitors and their therapeutic use)

RN 606099-92-7 CAPLUS
CN Carbamic acid, [5-[4-[[[(3-bromophenyl)amino]carbonyl]amino]phenyl]-6-methylfuro[2,3-d]pyrimidin-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 606099-89-2P 606099-90-5P 606099-91-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(pyrazolopyrimidine and furopyrimidine protein kinase inhibitors and their therapeutic use)
RN 606099-89-2 CAPLUS
CN Carbamic acid, [5-(4-nitrophenyl)furo[2,3-d]pyrimidin-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 606099-90-5 CAPLUS
CN Carbamic acid, [6-bromo-5-(4-nitrophenyl)furo[2,3-d]pyrimidin-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 606099-91-6 CAPLUS
CN Carbamic acid, [6-bromo-5-[4-[[[(3-methylphenyl)amino]carbonyl]amino]phenyl]furo[2,3-d]pyrimidin-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2003:221693 CAPLUS
DOCUMENT NUMBER: 138:238197
TITLE: Preparation of furo- and thienopyrimidines as TIE-2 and/or VEGFR-2 kinase inhibitors useful against hyperproliferative diseases
INVENTOR(S): Adams, Jerry Leroy; Bryan, Deborah Lynne; Feng, Yanhong; Matsunaga, Shinichiro; Maeda, Yutaka; Miyazaki, Yasushi; Nakano, Masato; Rocher, Jean-Philippe; Sato, Hideyuki; Semones, Marcus; Silva, Domingos J.; Tang, Jun
PATENT ASSIGNEE(S): Glaxosmithkline K.K., Japan; Smithkline Beecham Corporation
SOURCE: PCT Int. Appl., 265 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003022852	A2	20030320	WO 2002-US28650	20020910
WO 2003022852	A3	20031127		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002333524	A1	20030324	AU 2002-333524	20020910
EP 1425284	A2	20040609	EP 2002-798181	20020910
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, SK				
JP 2005508904	T	20050407	JP 2003-526926	20020910
US 20050004142	A1	20050106	US 2004-489052	20040309
US 7427623	B2	20080923		
US 20080287466	A1	20081120	US 2008-169800	20080709
PRIORITY APPLN. INFO.:			US 2001-318766P P	20010911
			WO 2002-US28650 W	20020910
			US 2004-489052 A3	20040309

OTHER SOURCE(S): MARPAT 138:238197
GI



I

AB Furo- and thienopyrimidine derivs. (shown as I; variables defined below; e.g. 4-Amino-3-(4-methoxyphenyl)-2-[3-(methylsulfonylamino)phenyl]furo[2,3-d]pyrimidine), which are useful as TIE-2 (tyrosine kinase containing immunoglobin and EGF homol. domains) and/or VEGFR-2 kinase inhibitors against hyperproliferative diseases are described herein. Enzyme inhibitions by .apprx.60 examples of I are included as ranges; also, 4-amino-3-[4-[[2-fluoro-5-(trifluoromethyl)phenyl]aminocarbonylamino]phenyl]thieno[2,3-d]pyrimidine exhibited IC50 = 0.0018 μM in the TIE-2 fluorescence polarization kinase activity assay. For I: X is O or S; A is H, halo, C1-C6 alkyl, aryl, heteroaryl, aryl or heteroaryl substituted with ≥1 R3, heterocyclyl, -RR3, -C(O)OR4, -C(O)NR5R6, -C(O)R4; D is H, halo, C1-C6 alkyl, aryl, heteroaryl, aryl or heteroaryl substituted with ≥1 R3, heterocyclyl, -RR3, -C(O)OR4, -C(O)NR5R6, or -C(O)R4. R is C1-C6 alkylene, C3-C7 cycloalkylene, C1-C6 alkenylene, or C1-C6 alkynylene; R1 is H, C1-C6 alkyl, C1-C6 alkoxy, -SR4, -S(O)2R4, -NR7R7, -NR'N R'''R'''', -N(H)RR3, -C(O)OR7, or -C(O)NR7R7. R2 is H, -OH, -NR7R7 or :NH; R3 is halo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C3-C7 cycloalkoxy, C1-C6 haloalkoxy, aryl, aralkyl, aryloxy, heteroaryl, heterocyclyl, -CN, -NHC(O)R4, -N(R8)HC(O)R4, -NHC(S)R4, -NR5R6, -RNR5R6, -SR4, -S(O)2R4, -RC(O)OR4, -C(O)OR4, -C(O)R4, -C(O)NR5R6, -NHS(O)2R4, -N(S(O)2R4)S(O)2R4, -S(O)2NR5R6, or -NHC(:NH)R4. R4 is H, C1-C6 alkyl, aryl, heteroaryl, heterocyclyl, -RR3, -NR'''R'''', or - NR'NR'''R''''; R5 is H, C1-C6 alkyl, C3-C7 cycloalkyl, cyanoalkyl, -R'R'', aryl, aralkyl, heteroaryl, -NHC(O)OR''', -R'NHC(O)OR''', -R'NHC(O)NR'''R'''', or -R'C(O)OR'''. R6 is H, C1-C6 alkyl, C3-C7 cycloalkyl, cyanoalkyl, -R'R'', aryl, aralkyl, heteroaryl, -C(O)OR''', or -R'C(O)NR'''R'''; R7 is H, C1-C6 alkyl, aryl, or -C(O)OR'''; R8 is C1-C3 alkyl; R' is C1-C3 alkylene; R'' is heteroalkyl or NRR'''R''''; R''' is H, C1-C6 alkyl, aryl, aralkyl, heteroaryl, or C3-C7 cycloalkyl; R'''' is H, C1-C6 alkyl, aryl, heteroaryl, or C3-C7 cycloalkyl. Although the methods of preparation are not claimed, several example prepns. of I are included and characterization data is given for .apprx.480 examples of I.

IT 501694-28-6P, 4-Benzyloxycarbonylamino-5-(4-methoxyphenyl)furo[2,3-d]pyrimidine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of furo- and thienopyrimidines as TIE-2 and/or VEGFR-2 kinase inhibitors useful against hyperproliferative diseases)
RN 501694-28-6 CAPLUS
CN Carbamic acid, [5-(4-methoxyphenyl)furo[2,3-d]pyrimidin-4-yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 10 OF 13 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L7 ANSWER 11 OF 13 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1999:68725 CAPLUS
DOCUMENT NUMBER: 130:237524
TITLE: Synthesis of certain furopyrimidines as potential antitumor agents
AUTHOR(S): Swelam, S. A.
CORPORATE SOURCE: National Research Centre, Cairo, Egypt
SOURCE: Indian Journal of Heterocyclic Chemistry (1998), 8(2),
147-150
CODEN: IJCHEI; ISSN: 0971-1627
PUBLISHER: Prof. R. S. Varma
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



AB 2-Amino-4,5-diphenyl-3-furancarbonitrile was converted to furothiazine I (X = S), which was oxidized to I (X = O). I were converted to a variety of heterocycles, e.g., II (NH2, C6H4F-4, C6H4OMe-4), III, and IV (same R).
Two of the products showed moderate antitumor activity against L1210 leukemia in mice.
IT 221343-02-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(furopyrimidines as potential antitumor agents)
RN 221343-02-8 CAPLUS
CN Ethanamine, 1,1-diethoxy-N-(2-methyl-6,7-diphenyl-8H-furo[2,3-d][1,3,4]thiadiazolo[3,2-a]pyrimidin-8-ylidene)- (CA INDEX NAME)

L7 ANSWER 11 OF 13 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L7 ANSWER 12 OF 13 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1995:537697 CAPLUS
DOCUMENT NUMBER: 123:83235
ORIGINAL REFERENCE NO.: 123:14897a,14900a
TITLE: Synthesis of furo[2,3-d]pyrimidines and furo[2,3-b]pyridines
AUTHOR(S): Ali, M. M.; Zahran, M. A.; Ammar, Y. A.; Mohamed, Y. A.; Seleim, A. T.
CORPORATE SOURCE: Fac. Science, Al-Azhar Univ., Nasr, Egypt
SOURCE: Indian Journal of Heterocyclic Chemistry (1995), 4(3),
191-4
CODEN: IJCHEI; ISSN: 0971-1627
PUBLISHER: Lucknow University, Dep. of Chemistry
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Condensation of 2-amino-3-cyano-4,5-bis(3,4,5-trimethoxyphenyl)furan (I) with isothiocyanates, urea or thiourea, and carbon disulfide furnished furopyrimidine derivs., resp. Interaction of I or 2-amino-3-cyano-4,5-diphenylfuran (II) with formamide and Et acetoacetate afforded furopyridine derivs., resp. 4-Aminofuropyrmidines have been converted into 4-imide, diacetyl, and benzamide derivs. Interaction of II
with succinic anhydride gave the amide derivative, which cyclized to tetrahydrofuranone derivative
IT 165400-69-1P 165400-70-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis of furo[2,3-d]pyrimidines, furo[2,3-b]pyridines, and related
compds.)
RN 165400-69-1 CAPLUS
CN Acetamide, N-acetyl-N-(5,6-diphenylfuro[2,3-d]pyrimidin-4-yl)- (CA INDEX NAME)



RN 165400-70-4 CAPLUS
CN Benzamide, N-(5,6-diphenylfuro[2,3-d]pyrimidin-4-yl)- (CA INDEX NAME)



L7 ANSWER 13 OF 13 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1970:12673 CAPLUS
DOCUMENT NUMBER: 72:12673
ORIGINAL REFERENCE NO.: 72:2305a,2308a
TITLE: Synthesis of furan derivatives. XLVIII. Synthesis of difurylfuro [2,3-d] pyrimidines and difurylfuro-[3,2-d]-s-triazolopyrimidines
AUTHOR(S): Saikachi, Haruo; Matsuo, Junro; Matsuda, Takumi
CORPORATE SOURCE: Fac. Pharm. Sci., Kyushu Univ., Fukuoka, Japan
SOURCE: Yakugaku Zasshi (1969), 89(10), 1434-9
CODEN: YKKZAJ; ISSN: 0031-6903
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB 2-Amino-3-cyano-4,5-di-2-furylfuran (I), obtained from furoin and malononitrile, was reacted with CS2, HCONH2, and imino ethers, and 2-(ethoxymethyleneamino)-3-cyano-4,5-di(2-furyl)furan, obtained from the reaction of I and HC(OEt)3, was reacted with NH3 and H2NNH2 to obtain the corresponding difurylfuro[2,3-d]pyrimidines. 3-Amino-4-(3H)-iminofuro[2,3-d]pyrimidine (II) underwent rearrangement to 4-hydrazinodifurylfuro[2,3-d]pyrimidine (III) on being heated. The reaction of II and III with HC(OEt)3 or Ac2O afforded the corresponding furo[3,2-d]-s-triazolo[2,3-d]pyrimidines (IV and V), as well as -furo[3,2-d]-s-triazolo[3,4-c]pyrimidines which upon heating in pyrimidine rearranged to IV and V.
IT 24386-19-4P 24386-20-7P 24386-24-1P 24386-25-2P 24386-27-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 24386-19-4 CAPLUS
CN Acetamide, N-(5,6-di-2-furanylfuro[2,3-d]pyrimidin-4-yl)- (CA INDEX NAME)



RN 24386-20-7 CAPLUS
CN Acetamide, N-[5,6-bis(5-nitro-2-furanyl)furo[2,3-d]pyrimidin-4-yl]- (CA INDEX NAME)



L7 ANSWER 13 OF 13 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RN 24386-24-1 CAPLUS
CN Acetamide, N-(5,6-di-2-furanyl-2-methylfuro[2,3-d]pyrimidin-4-yl)- (CA INDEX NAME)



RN 24386-25-2 CAPLUS
CN Acetamide, N-acetyl-N-(5,6-di-2-furanyl-2-methylfuro[2,3-d]pyrimidin-4-yl)- (CA INDEX NAME)



RN 24386-27-4 CAPLUS
CN Acetic acid, 1,2-diacetyl-2-(5,6-di-2-furanylfuro[2,3-d]pyrimidin-4-yl)hydrazide (CA INDEX NAME)



```
=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                    73.82     301.08

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                   -10.66     -10.66

STN INTERNATIONAL LOGOFF AT 07:42:39 ON 24 MAR 2009
```